ArticleExperimental hematology & oncology2015

Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.

Katherine Linder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.